Publication: Ovarian metastasis and other ovarian neoplasms in women with cervical cancer stage IA-IIA
Issued Date
2012-01-01
Resource Type
ISSN
2476762X
15137368
15137368
Other identifier(s)
2-s2.0-84874015816
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Asian Pacific Journal of Cancer Prevention. Vol.13, No.9 (2012), 4525-4529
Suggested Citation
Vijit Ngamcherttakul, Irene Ruengkhachorn Ovarian metastasis and other ovarian neoplasms in women with cervical cancer stage IA-IIA. Asian Pacific Journal of Cancer Prevention. Vol.13, No.9 (2012), 4525-4529. doi:10.7314/APJCP.2012.13.9.4525 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/13843
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Ovarian metastasis and other ovarian neoplasms in women with cervical cancer stage IA-IIA
Author(s)
Other Contributor(s)
Abstract
Objectives: To determine the prevalence and predicting factors of ovarian metastasis, and evaluate the histology of other ovarian neoplasms in women with early-stage cervical cancer. Methods: The medical records of women with cervical cancer stage IA-IIA who underwent primary surgical treatment at Siriraj Hospital, Mahidol University from January 2007 to December 2011 were used for the study. Demographic, clinical and histopathologic data of the women who underwent salpingo-oophorectomy were reviewed. Results: Of 264 women, the mean age was 52.3 years. The types of hysterectomy procedures were composed of 210 radical hysterectomy, 9 modified radical hysterectomy, 40 simple hysterectomy, and 5 abandoned hysterectomy. The prevalence of ovarian metastasis was 0.76% (2/264). All of ovarian metastatic patients were older than 60 years old, postmenopause, and had macroscopical stage IB1 cervical cancer. Others ovarian tumors were found in 7 patients including 1 synchronous ovarian carcinoma, 1 serous cystadenoma, 1 fibroma, and 4 teratoma. Conclusions: In cases of early-stage cervical carcinoma of the population studied, ovarian preservation could be another option in < 60-year-old patients, with non-neuroendocrine cell type, stage IA, and no extracervical or ovarian lesions.